Content
Search
Navigation
Sitemap
About us
Pipeline & science
Overview
Obesity
Acute Ischemic Stroke (AIS)
Hypertension
Our expertise
Overview
Our strategic partners
Global opportunities
Join us
Press releases
Contact
简体中文
Search
简体中文
Navigation
Press releases
21 Mar 2022
JIXING Announces Receipt of Clinical Trial Application Approval for OC-01 Nasal Spray Phase 3 Trial for the Treatment of Signs and Symptoms of Dry Eye Diseases in China
Read article
17 Mar 2022
JIXING Presents Results of China Phase I Study of Aficamten at the 2022 American Society for Clinical Pharmacology and Therapeutics Annual Meeting
Read article
16 Feb 2022
JIXING Announces Receipt of Breakthrough Therapy Designation for Aficamten in China
Read article
04 Feb 2022
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure with Reduced Ejection Fraction
Read article
20 Dec 2021
Cytokinetics and JIXING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
Read article
03 Dec 2021
JIXING Completes Phase 1 Study of Aficamten, a Potential Next-generation Cardiac Myosin Inhibitor, for Patients with Hypertrophic Cardiomyopathy (HCM)
Read article
Load more
